While most studies have been to establish safety and feasibility, limiting inclusion criteria to MGMT-promoter methylated GBM for FUS-enhanced TMZ therapies could improve outcomes due to epigenetic silencing. The gene discussed is MGMT; the disease is glioblastoma.